Macular degeneration primary prevention: Difference between revisions
Hardik Patel (talk | contribs) |
m Bot: Removing from Primary care |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 4: | Line 4: | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
==Primary Prevention== | ==Primary Prevention== | ||
The [[Age-Related Eye Disease Study]] showed that a combination of high-dose [[beta-carotene]], [[vitamin C]], [[vitamin E]], and [[zinc]] can reduce the risk of developing advanced AMD by about 25 percent in those patients who have earlier but significant forms of the disease. | The [[Age-Related Eye Disease Study]] showed that a combination of high-dose [[beta-carotene]], [[vitamin C]], [[vitamin E]], and [[zinc]] can reduce the risk of developing advanced AMD by about 25 percent in those patients who have earlier but significant forms of the disease. This is the only proven intervention to decrease the risk of advanced AMD at this time. A follow up study, Age-Related Eye Disease Study 2 to study the potential benefits of [[lutein]], [[zeaxanthin]], and fish oil, is currently underway. | ||
Anecortave acetate | Anecortave acetate (Retanne), is an anti-angiogenic drug that is given as an injection behind the eye (avoiding an injection directly into the eye) that is currently being studied as a potential way of reducing the risk of neovascular (wet) AMD in high-risk patients. | ||
Research started in 2005 has shown that intravitreal injection of Avastin (bevacizumab) can improve vision and slow down the macular degeneration. This therapy is currently being used in various centres around the world. Avastin is an immunoligic drug that prevents neovascularization. Hence it may also be effective in diabetic retinopathy. Avastin | Research started in 2005 has shown that intravitreal injection of [[Avastin]] (bevacizumab) can improve vision and slow down the macular degeneration. This therapy is currently being used in various centres around the world. Avastin is an immunoligic drug that prevents neovascularization. Hence it may also be effective in [[diabetic retinopathy]]. [[Avastin]] was initially used for the treatment of [[colorectal cancer]]. | ||
A study by a neuroretinologist in the late 80's suggested that microcurrent stimulation of acupuncture points for the eye had positive effects in slowing and even stopping progression of the disease. This study was based on Ngok Cheng's research on the increased amounts of ATP levels in living tissue after being stimulated with microcurrent. ("The Effects of Electric Currents on ATP Generation, Protein Synthesis, and Membrane Transport in Rat Skin | A study by a neuroretinologist in the late 80's suggested that microcurrent stimulation of acupuncture points for the eye had positive effects in slowing and even stopping progression of the disease. This study was based on Ngok Cheng's research on the increased amounts of [[ATP]] levels in living tissue after being stimulated with microcurrent. ("The Effects of Electric Currents on ATP Generation, Protein Synthesis, and Membrane Transport in Rat Skin") Several similar studies are currently being underway. | ||
Recent studies suggest that [[statin]]s, a family of drugs used for reducing [[cholesterol]] levels, may be effective in prevention of AMD, and in slowing its progression.<ref>http://bjo.bmjjournals.com/cgi/content/full/882/161</ref> | Recent studies suggest that [[statin]]s, a family of drugs used for reducing [[cholesterol]] levels, may be effective in prevention of AMD, and in slowing its progression.<ref>http://bjo.bmjjournals.com/cgi/content/full/882/161</ref> | ||
| Line 17: | Line 18: | ||
Studies are underway at Harvard, with the goal of reducing [[lipofuscin]] accumulation.<ref name=Harvard>John Lacey, "[http://www.eurekalert.org/pub_releases/2006-05/hms-hms052306.php Harvard Medical signs agreement with Merck to develop potential therapy for macular degeneration]", 23-May-2006</ref> | Studies are underway at Harvard, with the goal of reducing [[lipofuscin]] accumulation.<ref name=Harvard>John Lacey, "[http://www.eurekalert.org/pub_releases/2006-05/hms-hms052306.php Harvard Medical signs agreement with Merck to develop potential therapy for macular degeneration]", 23-May-2006</ref> | ||
On September 10, 2007, in a 6-year study, researchers, led by John Paul SanGiovanni of the [[National Eye Institute]], Maryland found that [[Lutein]] and [[zeaxanthin]] ([[nutrients]] in eggs, spinach and other green vegetables) protect against [[blindness]] (macular degeneration), affecting 1.2 million Americans, mostly after age 65. Lutein and zeaxanthin reduce the risk of [[AMD]] (journal [[Archives of Ophthalmology]]). Foods considered good sources of the nutrients also include kale, turnip greens, collard greens, romaine lettuce, broccoli, zucchini, corn, garden peas and Brussels sprouts. | On September 10, 2007, in a 6-year study, researchers, led by John Paul SanGiovanni of the [[National Eye Institute]], Maryland found that [[Lutein]] and [[zeaxanthin]] ([[nutrients]] in eggs, spinach and other green vegetables) protect against [[blindness]] (macular degeneration), affecting 1.2 million Americans, mostly after age 65. [[Lutein]] and [[zeaxanthin]] reduce the risk of [[AMD]] (journal [[Archives of Ophthalmology]]). Foods considered good sources of the nutrients also include kale, turnip greens, collard greens, romaine lettuce, broccoli, zucchini, corn, garden peas, and Brussels sprouts. | ||
==References== | ==References== | ||
| Line 23: | Line 24: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Optometry]] | [[Category:Optometry]] | ||
[[Category:Ophthalmology]] | [[Category:Ophthalmology]] | ||
| Line 30: | Line 32: | ||
[[Category:Aging-associated diseases]] | [[Category:Aging-associated diseases]] | ||
[[Category:Blindness]] | [[Category:Blindness]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
Latest revision as of 22:37, 29 July 2020
|
Macular degeneration Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Macular degeneration primary prevention On the Web |
|
American Roentgen Ray Society Images of Macular degeneration primary prevention |
|
Risk calculators and risk factors for Macular degeneration primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Primary Prevention
The Age-Related Eye Disease Study showed that a combination of high-dose beta-carotene, vitamin C, vitamin E, and zinc can reduce the risk of developing advanced AMD by about 25 percent in those patients who have earlier but significant forms of the disease. This is the only proven intervention to decrease the risk of advanced AMD at this time. A follow up study, Age-Related Eye Disease Study 2 to study the potential benefits of lutein, zeaxanthin, and fish oil, is currently underway.
Anecortave acetate (Retanne), is an anti-angiogenic drug that is given as an injection behind the eye (avoiding an injection directly into the eye) that is currently being studied as a potential way of reducing the risk of neovascular (wet) AMD in high-risk patients.
Research started in 2005 has shown that intravitreal injection of Avastin (bevacizumab) can improve vision and slow down the macular degeneration. This therapy is currently being used in various centres around the world. Avastin is an immunoligic drug that prevents neovascularization. Hence it may also be effective in diabetic retinopathy. Avastin was initially used for the treatment of colorectal cancer.
A study by a neuroretinologist in the late 80's suggested that microcurrent stimulation of acupuncture points for the eye had positive effects in slowing and even stopping progression of the disease. This study was based on Ngok Cheng's research on the increased amounts of ATP levels in living tissue after being stimulated with microcurrent. ("The Effects of Electric Currents on ATP Generation, Protein Synthesis, and Membrane Transport in Rat Skin") Several similar studies are currently being underway.
Recent studies suggest that statins, a family of drugs used for reducing cholesterol levels, may be effective in prevention of AMD, and in slowing its progression.[1]
Studies are underway at Harvard, with the goal of reducing lipofuscin accumulation.[2]
On September 10, 2007, in a 6-year study, researchers, led by John Paul SanGiovanni of the National Eye Institute, Maryland found that Lutein and zeaxanthin (nutrients in eggs, spinach and other green vegetables) protect against blindness (macular degeneration), affecting 1.2 million Americans, mostly after age 65. Lutein and zeaxanthin reduce the risk of AMD (journal Archives of Ophthalmology). Foods considered good sources of the nutrients also include kale, turnip greens, collard greens, romaine lettuce, broccoli, zucchini, corn, garden peas, and Brussels sprouts.